Promise and Peril: Navigating What's Next in Clinical Research

While 57% of pharma leaders expect budgets to increase, Eliassen Life Sciences Solutions research shows they remain confronted by familiar, high-stakes challenges. With drug development costs at $2.3 billion and trial failure rates near 90%, pharmaceutical organizations must navigate the promise of new technology against a complex regulatory landscape.

Explore our latest white paper to learn how biopharma directors and C-suite leaders are overcoming compliance hurdles, leveraging AI, and moving past under-performing outsourcing models to drive true R&D efficiency.

 

Get your white paper today.

Key Takeaways

Why pharma leaders are pivoting from traditional CROs to strategic partnerships.

The Budget

57%-1

of leaders expect budgets to increase this year.

The Stategy

28%-1

of organizations are expecting to increase use of outsourcing partners.

The Gap

2x-1

Traditional CRO users report more than double the issues with scaling.

The Challenge

22%-1

Cite Regulatory & Compliance as the #1 hurdle.

Top Growth Drivers

Innovative Trial Design (24%)  |  AI Implementation (21%)  |  Precision Medicine (20%)